KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Cash & Equivalents (2016 - 2026)

AbbVie has reported Cash & Equivalents over the past 14 years, most recently at $5.2 billion for Q4 2025.

  • Quarterly Cash & Equivalents fell 5.34% to $5.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Dec 2025, down 5.34% year-over-year, with the annual reading at $5.2 billion for FY2025, 5.34% down from the prior year.
  • Cash & Equivalents was $5.2 billion for Q4 2025 at AbbVie, down from $5.6 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $18.1 billion in Q1 2024 and troughed at $5.2 billion in Q1 2025.
  • The 5-year median for Cash & Equivalents is $8.7 billion (2021), against an average of $9.2 billion.
  • Year-over-year, Cash & Equivalents tumbled 76.29% in 2021 and then skyrocketed 169.21% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $9.7 billion in 2021, then decreased by 5.59% to $9.2 billion in 2022, then surged by 39.27% to $12.8 billion in 2023, then crashed by 56.89% to $5.5 billion in 2024, then decreased by 5.34% to $5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Cash & Equivalents are $5.2 billion (Q4 2025), $5.6 billion (Q3 2025), and $6.5 billion (Q2 2025).